The Global Digital Therapeutics (DTx) Market was valued US$ 4.28 billion in 2021 and is predictable to reach US$ 16.13 billion by 2028; growing at a CAGR of 20.9% from 2021 to 2028. DTx delivers evidence-based therapies through software like health apps application that replaces or enhance the existing treatment of a disease. They diverge from the broader digital health market in which they must be approved by regulatory bodies and displaying demonstrate at the core of their model. These factors are in turn expected to drive the growth of digital therapeutics market size. The growing adoption of smartphones and tablets, coupled with healthcare apps, the growing need to control healthcare costs, and the rise in cases of chronic diseases are expected to fuel the growth of the digital therapeutics market.
Digital Therapeutics Market Dynamics
Chronic diseases have increased the implication on healthcare systems across the globe. Cardiovascular disease (CVD) is the leading cause of death globally as it accounts 17.3 million deaths per year. In many countries, various health apps are under necessary approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security. Digital therapeutics providers have access to patient information and are restricted from sharing the information with anyone not involved in treating that patient but with the integration of data using digital tools, the patient’s data is at risk of being obtain by any healthcare professional who are not related to the patient’s treatment program. Emerging economies such as India, China, and the Middle East present growth opportunities for digital therapeutics. In most region, the market is still in its infancy due to lack of awareness, minimum availability of solutions, lack of IT infrastructure, and financial and social constraints. On other hand, most emerging economies show high rates of chronic disease incidence. It is expected that chronic diseases will be responsible for 70% of the total deaths in developing countries and on the global level by 2025, ~60% of the chronic conditions will be in developing countries. Motivating the people to use digital therapeutics by building their confidence is a major challenge faced by digital therapeutics providers although older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, it is unclear whether digital therapeutics market can sustain longer periods. Many patients still rely on traditional means of diagnosis and treatment and shows hesitancy to adopt these therapies. This poses a major challenge to the digital therapeutics market
The prominent players in the digital therapeutics market include Noom, Livongo Health, Omada Health, WellDoc, Pear Therapeutics, Proteus Digital Health, Propeller Health, Akili Interactive Labs, Better Therapeutics, Happify, Kaia Health, Mango Health, Click Therapeutics, Canary Health, Wellthy Therapeutics, Cognoa, CogniFit, Ayogo Health, Mindstrong Health, 2Morrow, and Ginger among others.
The digital therapeutics market is categorized into the following segments and subsegments:
The global Digital Therapeutics Market is fragmented in terms of number of players. Key players in the global market include: